McKesson - "Hold" Still Valid In 2026
McKesson (MCK) remains a leading pharmaceutical distributor with strong fundamentals, but faces challenges from high valuation, regulatory pressures, and reliance on GLP-1 drug revenues. The stock's current price-to-earnings ratio of over 21x is seen as unattractive given potential margin compression and market uncertainties. As a result, a 'Hold' rating with a $510 price target is maintained due to limited upside and elevated risks.
- ▪McKesson is assigned a 'Hold' rating with a $510 per share price target.
- ▪The company's valuation exceeds 21 times earnings, which is considered high relative to risks.
- ▪A significant portion of McKesson's recent growth is tied to high-priced drugs and GLP-1 revenues.
- ▪Regulatory pressures and margin compression are key concerns affecting future performance.
- ▪McKesson maintains a leading position in the U.S. pharmaceutical distribution market.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4897426-mckesson-hold-still-valid-in-2026"},"author":{"@type":"Person","name":"Wolf Report","url":"https://seekingalpha.com/author/wolf-report"},"publisher":{"@context":"http://schema.org","@type":"Organization","address":{"@type":"PostalAddress","streetAddress":"244 5th Ave","addressLocality":"New…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
